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ABSTRACT 
Objective: This study aimed to enhance the solubility of simvastatin using noncovalent derivatives (NCDs) with oxalic acid (OA), fumaric acid (AF), 
and nicotinamide (NK) as conformers.  
Methods: NCDs were prepared using by a solvent drop grinding (SDG). The NCDs formed were evaluated for saturated solubility test, NCDs with the 
highest saturation solubility were then characterized by Fourier transform infrared spectrophotometry (FT-IR), differential scanning calorimeter 
(DSC), powder x-ray diffractometry (PXRD) and the particulate dissolution using type II of USP test. 
Results: SV-OA NCDs showed the highest solubility; thus NCDS of SV-OA were characterized by X-ray diffraction showing a new peak at 2ϴ = 28.96 
°C and differential scanning calorimeter showed a change of endothermic peak from 134.3 °C to 69 °C. Infrared spectroscopy indicated that there 
were no functional group changes from simvastatin, while the dissolution rate increased from 68.22% to 76.08%. 
Conclusion: 
Keywords: Simvastatin, Non-covalent derivative, Solvent drop grinding, Dissolution 
SV-OA NCDs show an increased profile of solubility and dissolution compared to pure simvastatin. 
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INTRODUCTION 
Biological availability is a rate value and the quantity of the drug that 
reaches the blood circulation. Solubility is an important factor in 
predicting the bioavailability of drugs in blood circulation. Often, 
drugs that have poor solubility in water also show low 
bioavailability, so the dissolution rate is the rate-limiting step in the 
absorption process of drugs in the body. The solubility of a drug is 
related to its physicochemical properties [1, 2]. 
Simvastatin is a drug that inhibits the action of the HMG-CoA reductase 
enzyme, thereby helping to reduce cholesterol levels in the blood. Based 
on the results of the Scandinavian Simvastatin Survival Study (4S) and 
The Heart Protect Study (HPS), simvastatin can reduce the incidence of 
ischemic stroke, myocardial infarction, and death in cardiovascular 
patients with atherosclerosis and hypercholesterolemia [3]. 
Based on the Biopharmaceutical Classification System (BCS), simvastatin 
is a class II drug group that has low water solubility but high 
permeability. High solubility can increase the bioavailability of drugs, so 
solubility is a determining factor in the quantity of the drug reaching the 
systemic circulation system [4]. Therefore, efforts should be made to 
increase the solubility of simvastatin to increase its bioavailability. 
There are various ways to increase the speed of testing, the rate of 
dissolution or solubility of a drug, including the pro-drug approach, salt 
form synthesis, particle size reduction, complex formation, physical 
shape changes, solid dispersion, spray drying, and hot-melt extrusion. 
One technique with physical shape changes in the formation of co-
crystalline techniques which causes changes in the arrangement of the 
molecules making up the crystal is caused by the formation of hydrogen 
bonds between the active substance and the co-former. Changes in the 
crystal lattice will cause increased changes in solubility [5]. In this study, 
an effort to increase the rate of dissolution of simvastatin will be 
investigated using oxalic acid, fumaric acid and nicotinamide as a 
coformer with a noncovalent derivative approach. 
MATERIALS AND METHODS  
Tools 
Spectrophotometer UV-Vis (Specord 200), mechanic agitator (Ohm), 
Spectrophotometer FTIR (Specord), dissolution tester (Sotax AT7), 
X-Ray Diffractometer (Philips PW 1835), Differential Scanning 
Calorimetry (Pan analytical). 
Materials 
The following materials were used: simvastatin (98%, Teva, Belgium), 
nicotinamide (Sigma Aldrich), fumaric acid (Sigma Aldrich), oxalic acid 
(Merck), methanol (Merck), sodium dodecyl sulfate (Merck), sodium 
phosphate (Merck), and sodium hydroxide (Merck). 
Methods 
Production of simvastatin NCDs by the solvent drop grinding 
method 
Simvastatin (SV) was mixed in a 1:1 ratio with nicotinamide (NK), 
oxalic acid (AO), or fumaric acid (AF) in a mortar and then crushed 
for 20 min with the dropwise addition of methanol. 
Saturated solubility test 
The equivalent to 20 mg simvastatin was dissolved with 10 ml 
aquades in an Erlenmeyer, placed in a mechanical agitator for 48 h 
at room temperature (25 °C) and then the saturated solubility was 
measured by UV spectrophotometry in the wavelength range of 
247–257 nm [6]. 
Characterization of NCDs 
X-ray diffraction analysis 
The crystal structure was analyzed using a Powder X-Ray 
Diffractometer (Philips PW 1835), with the following conditions: 
target/filter (monochromator) Cu, voltage 40 kV, current 30 mA, slit 
width of 0.2 inches, with a scanning speed of 0.2–0.5 °/min and 
scanning distance 2θ = 5–60 ° [6].  
Fourier-transform infrared spectroscopy (FTIR)  
Powder-shaped samples were mixed with potassium bromide 
crystals at a molar ratio of 1:10 and crushed until homogeneous, 
then compressed with a pressure of 20 Psi using a KBr plate press. 
Spectra were measured in the range of 4000–400 cm-1 using a FTIR 
spectrophotometer [6]. 
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Differential scanning calorimetry (DSC) 
A sample of 3–5 mg was placed in the device programmed in a 
temperature range of 50–350 °C with a heating speed of 10 °C/min [6]. 
Dissolution test 
The dissolution rate test was conducted based on USP30-NF25 using 
Apparatus 2 (paddle) with a speed of 50 rpm for 30 min and 900 ml 
media buffer solution pH 7 at 37±0.2 °C. Periodically every 10 min, 5 
ml was sampled and the media replaced with the same volume 
during the test. Samples were then measured using UV 
spectrophotometry in the wavelength range of 247–257 nm to 
calculate the dissolution rate [6]. 
RESULTS AND DISCUSSION 
Production of simvastatin NCDs by the solvent drop grinding 
method 
Simvastatin co-crystals are made using the solvent drop grinding 
(SDG) method. This method is used because it requires only a few 
solvents where the solvent is dropped during grinding so it is more 
cost-effective and more environmentally friendly than the solution-
based method [7]. Co-crystals are made by mixing simvastatin with 
co-former using a 1: 1 equimolar ratio (table 1). The comparison 
used refers to some previous research journals and theses that 
report the best results of NCDs formed with a 1: 1 equlmolar ratio [8, 
9]. Co-former is used to help the formation of simvastatin co-crystals 
where the ethanol solvent functions as a catalyst. The active and co-
former substances must have a number of donors and hydrogen 
bond acceptors. This hydrogen bond is an important bond in the 
formation of NCDs because the more hydrogen bonds, the solubility 
of a substance will increase. Another requirement of the co-former is 
that it must be pharmacologically acceptable, non-toxic and 
pharmacologically inert and can be easily dissolved in water. Three 
co-former used in this study fulfills these requirements. In addition, 
these three co-formers were reported to be proven to form co-
crystals through hydrogen bonds [5, 8, 9, 11, 12]. In the process of 
making NCDs, weight loss ranges from 16-20%. Losses occur 
because there is material left behind at the time of final weighing 
after grinding. 
 
Table 1: Comparison of simvastatin and co-former weights 
API: co-former Molar comparison Weight comparison (mg) 
SV: NK 1:1 100: 29 
SV: AF 1:1 100: 22 
SV: AO 1:1 100: 24 
Number of experiment (n=3) 
 
Solubility test results 
The solubility test was conducted on simvastatin and the simvastatin 
NCDs with the three co-formers, namely nicotinamide, fumaric acid 
and oxalic acid. The solubility test was conducted to determine the 
effect of the co-former which gave the highest increase in the 
solubility of the three co-formers used. From the solubility test 
results, the co-former which formed the highest solubility was oxalic 
acid (3 ppm; fig. 1). 
NCDs characterization 
Powder X-ray diffraction 
The results of X-ray diffraction showed the formation of a new peak 
on the diffractogram at 2ϴ at 28.96°. Changes in diffraction patterns 
and the formation of new peaks on diffractograms indicate the 
formation of NCDs [13]. 
FT-IR spectrophotometric analysis 
Infrared spectroscopy tests were performed on standard simvastatin, 
oxalic acid, and simvastatin co-crystals. Infrared spectroscopy is often 
used to detect interactions between drugs and coformer in NCDs. 
Infrared spectroscopy can detect cocrystal formations, as seen from 
the presence of hydrogen bonds. Cocrystallization between 
simvastatin with oxalic acid causes complexation between the two. 
The interaction between the two substances is linked by hydrogen 
bonds. Hydrogen bonds are formed due to the presence of a carbonyl 
group from simvastatin which will bind to the hydroxy group on oxalic 
acid. The hydrogen bonding spectrum will appear at wavenumbers 
3600-3200 cm-1 
Based on the results of the infrared absorption spectrum, the 
interaction of hydrogen bonds between simvastatin and oxalic acid 
was evident as the absorption band C=O ester of the standard 
simvastatin at 1700.32 cm
[14]. 
-1 shifted to 1704.18 cm-1
Differential scanning calorimetry  
 on the 
simvastatin co-crystals. This indicates that the expected hydrogen 
bonds have form3ed in the NCDs. Electronegative elements tend to 
attract electrons in between the carbon and oxygen atoms in the C=O 
bond, so that the bond becomes stronger; therefore the vibration 
band C=O bonds appear at higher frequencies [13]. From the shape 
of the spectrum image, it is evident that there is no change in the 
functional group of simvastatin. 
The formation of physical interactions between two materials can be 
estimated using thermal analysis [14] if there is a change in the 
shape of the crystals, there will be changes in the thermodynamic 
aspects of a solid [15]. Screening the formation of physical 
interactions between simvastatin and oxalic acid was detected by 
DSC, as shown in fig. 4. 
 
 
Fig. 1: Solubility of SV and SV-NCDs (n=3) 
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Fig. 2: X-ray diffractogram of SV, NCDs (SV-OXA), and oxalic acid (n=3) 
 
 
Fig. 3: Infrared spectrum overlay cocrystalline simvastatin (purple) with standard simvastatin (black) 
 
 
Fig. 4: Thermogram overlay of simvastatin, NCDs, oxalic acid 
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The standard simvastatin thermogram shows an endothermic peak, 
which is the melting process of crystal solids with an onset 
temperature of 120.8 °C, maximum peak at 134.3 °C and enthalpy of-
105.68 J/g. The oxalic acid thermogram showed an endothermic 
peak with an onset temperature of 68.8 °C, maximum peak at 111.2 
°C and enthalpy of-689.77 J/g. The co-crystal thermogram shows an 
endothermic peak with an onset temperature of 48.0 °C, maximum 
peak at 62.9 °C and enthalpy of-232.35 J/g. Changes in the values of 
the maximum onset, peak temperatures and enthalpy values show 
the different characteristics of standard simvastatin, co-former 
oxalic acid and the resulting NCDs. It appears that there is a decrease 
in the value of the onset temperature, the maximum peak and the 
enthalpy value, indicating that NCDs require less heat than the 
standard simvastatin (1). 
Dissolution rate test 
The dissolution rate was measured by the amount of active 
substance dissolved in a certain time in a known volume of the liquid 
medium at a relatively constant temperature to determine how 
much standard simvastatin and NCDs were dissolved in a certain 
condition. There was an increase in the dissolution rate of standard 
simvastatin with NCDs of 3.14% at the 10th
 
 minute; 5.53% at 20 min 
and 7.86% at 30 min [16, 17]. 
 
Fig. 5: Dissolution profile of simvastatin () and NCDs () (n=3) 
 
CONCLUSION 
Simvastatin crystals were prepared using the SDG method. 
Characterization of the crystals by X-ray diffraction revealed a new 
peak on the diffractogram at 2ϴ = 28.96 ° and differential scanning 
calorimetry showed changes in the endothermic peak from 134.3 °C 
to 62.9 °C, while IR spectroscopy showed that there was no change 
in the functional group of simvastatin. The solubility test results 
showed the highest increase in solubility was achieved by co-
crystals formed by oxalic acid (3 ppm) and the dissolution rate 
increased from 68.22% to 76.08%. Further research is needed to 
test the bioavailability and stability of the resulting co-crystals, as 
well as investigate other methods and co-formers to produce co-
crystals that have the best solubility. 
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